French prospective multicenter, open-label study involving newly diagnosed CML patients. Two assessments will be performed during the follow-up of these patients: individual frailty using geriatric tools and individual biological aging determined by DNA methylation analysis.
Age ≥18 years
CML in chronic phase at time of diagnosis. Diagnosis must be made no more than 3 months (90 days) prior to inclusion. Diagnosis of chronic-phase CML (European Leukemia Network [ELN] 2020 criteria; Baccarani et al 2013) with confirmation of a Philadelphia chromosome (Ph1). A cryptic Ph1 chromosome must be confirmed by FISH.Criteria must meet the definition of chronic phase CML
BCR ::ABL1 transcript quantifiable by quantitative PCR
1st-line treatment with tyrosine kinase inhibitor
CML in accelerated or blast phase
Refusal to participate in the study
Treatment started prior to inclusion
Patients under guardianship, curatorship, deprivation of liberty or safeguard of justice